DDI-DrugBank.d610.s0 >> Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. >> 30-37,82-91,96-105,129-138,144-153
DDI-DrugBank.d610.s1 >> No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. >> 37-46,51-60,133-140
DDI-DrugBank.d610.s2 >> Abacavir has no effect on the pharmacokinetic properties of ethanol. >> 0-7,60-66
DDI-DrugBank.d610.s3 >> Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. >> 0-6,37-44,104-112,188-195
DDI-DrugBank.d610.s4 >> In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). >> 49-57,118-123,182-190
DDI-DrugBank.d610.s5 >> This alteration will not result in a methadone dose modification in the majority of patients; >> 37-45
DDI-DrugBank.d610.s6 >> however, an increased methadone dose may be required in a small number of patients. >> 22-30
